NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$91.76 -1.76 (-1.88 %)
(As of 11/15/2018 08:06 AM ET)
Previous Close$93.52
Today's Range$90.8650 - $94.83
52-Week Range$75.81 - $106.74
Volume1.12 million shs
Average Volume1.29 million shs
Market Capitalization$16.57 billion
P/E Ratio-136.96
Dividend YieldN/A
Beta1.65
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
Previous Symbol
CUSIP09061G10
Phone415-506-6700

Debt

Debt-to-Equity Ratio0.28
Current Ratio2.87
Quick Ratio2.26

Price-To-Earnings

Trailing P/E Ratio-136.96
Forward P/E Ratio-655.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.31 billion
Price / Sales12.44
Cash FlowN/A
Price / CashN/A
Book Value$16.37 per share
Price / Book5.61

Profitability

EPS (Most Recent Fiscal Year)($0.67)
Net Income$-117,040,000.00
Net Margins-8.35%
Return on Equity-2.98%
Return on Assets-1.83%

Miscellaneous

Employees2,581
Outstanding Shares178,060,000
Market Cap$16.57 billion
OptionableOptionable

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Thursday, October, 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.15. The biotechnology company earned $391.71 million during the quarter, compared to analyst estimates of $369.43 million. BioMarin Pharmaceutical had a negative net margin of 8.35% and a negative return on equity of 2.98%. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for BioMarin Pharmaceutical.

What price target have analysts set for BMRN?

19 equities research analysts have issued 12 month target prices for BioMarin Pharmaceutical's stock. Their predictions range from $92.00 to $145.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $118.3889 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.

What is the consensus analysts' recommendation for BioMarin Pharmaceutical?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. Cantor Fitzgerald analysts commented, ". Reiterate OW and $126 PT. We think progress updates at R&D day today were supportive of the pipeline’s long-term potential. Key takeaways: New vosoritide data was supportive of Ph3 success and BMRN sounds more confident in Valrox accelerated filing after further regulatory interactions. We continue to think that the company’s pipeline is undervalued at this level and we see highly favorable risk/reward into key pipeline updates in 2019. We think the base business alone (without any pipeline) is worth ~$85-$95/sh and that the company’s powerful rare disease and gene therapy platform is underappreciated." (11/4/2018)
  • 2. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. The latest FDA approval of Palynziq was the second product approval for BioMarin in less than two years, the first being Brineura in mid-2017. Its impressive rare disease pipeline is also progressing well. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has outperformed the industry so far this year. Estimates have gone up slightly ahead of the company’s Q3 earnings. However, BioMarin has a rather negative record of earnings surprises in the recent quarters." (10/5/2018)
  • 3. JPMorgan Chase & Co. analysts commented, "BMRN reported an in-line 2Q after the close. Our focus was on early commentary around the Palynziq rollout, which sounds quite favorable relative to prevailing expectations. With solid commercial progress (targeting ~$2B in sales by 2020 pre potential impact of val rox and vosoritide) and major clinical catalysts on the horizon for 2019/20, we continue to have a high level of conviction in the long-term outlook for BMRN. Reiterate OW." (8/5/2018)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

Media stories about BMRN stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of 1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the next several days.

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:
  • Mr. Jean-Jacques Bienaimé MBA, Chairman & CEO (Age 65)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 63)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60)

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (10.98%), Primecap Management Co. CA (7.98%), Jennison Associates LLC (6.09%), Capital World Investors (1.38%), Capital International Investors (1.18%) and Manning & Napier Group LLC (0.79%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Jennison Associates LLC, American Century Companies Inc., Manning & Napier Group LLC, USS Investment Management Ltd, FIL Ltd, Mitsubishi UFJ Trust & Banking Corp and Pictet Asset Management Ltd.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, First Trust Advisors LP, Hsbc Holdings PLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Sphera Funds Management LTD. and Fosun International Ltd. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $91.76.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $16.57 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is http://www.bmrn.com.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,105 (Vote Outperform)
Underperform Votes:  554 (Vote Underperform)
Total Votes:  1,659
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel